Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Joel, Raskin"'
Autor:
Li Shen Loo, Brian M. Plato, Ira M. Turner, Michael G. Case, Joel Raskin, Sherie A. Dowsett, John H. Krege
Publikováno v:
BMC Neurology, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. Methods SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies in which individuals with migraine were randomize
Externí odkaz:
https://doaj.org/article/5e769cb75cfb4af982fa00f4eeb0282c
Autor:
Jan Lewis Brandes, Suzanne Klise, John H Krege, Michael Case, Rashna Khanna, Raghavendra Vasudeva, Joel Raskin, David Kudrow
Publikováno v:
Cephalalgia Reports, Vol 3 (2020)
GLADIATOR was a prospective, randomized, open-label, phase 3 study of lasmiditan 100 mg or 200 mg dosed intermittently for up to 1 year in patients with episodic migraine. Most patients had completed one of two single-attack studies before participat
Externí odkaz:
https://doaj.org/article/3fee7067e3f8408fb5262cb1086b2615
Autor:
Catherine Reed, Mark Belger, Grazia Dell’Agnello, Kristin Kahle-Wrobleski, Gopalan Sethuraman, Ann Hake, Joel Raskin, David Henley
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-11 (2018)
Abstract Background Comparison of disease progression between placebo-group patients from randomised controlled trials (RCTs) and real-world patients can aid in assessing the generalisability of RCT outcomes. This analysis compared outcomes between c
Externí odkaz:
https://doaj.org/article/bec4068ab80e44c89ea1aa39626780f0
Autor:
Paul S. Aisen, Jeffrey Cummings, Clifford R. Jack, John C. Morris, Reisa Sperling, Lutz Frölich, Roy W. Jones, Sherie A. Dowsett, Brandy R. Matthews, Joel Raskin, Philip Scheltens, Bruno Dubois
Publikováno v:
Alzheimer’s Research & Therapy, Vol 9, Iss 1, Pp 1-10 (2017)
Abstract Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer’s disease (AD). It is now recognized that pathophysiological changes begin many years prior to clinical manifestations of disease
Externí odkaz:
https://doaj.org/article/cc9d4a43fe0c412baa97aca4e96639b8
Autor:
Jan Lewis Brandes, Raghavendra Vasudeva, John H. Krege, Suzanne Klise, Eric M. Pearlman, Michael Case, Joel Raskin, Rashna Khanna, David Kudrow
Publikováno v:
Cephalalgia
Objectives To address the need for long-term lasmiditan data, the GLADIATOR study evaluated the safety (primary) and efficacy (secondary) of lasmiditan for the intermittent, acute treatment of migraine attacks for up to 1 year. Methods In this prospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32721600b893e72c5c3b24947e48014c
https://doi.org/10.1177/0333102419864132
https://doi.org/10.1177/0333102419864132
Autor:
Brian M. Plato, Ira M. Turner, Sherie A. Dowsett, Li Shen Loo, John H. Krege, Joel Raskin, Michael Case
Publikováno v:
BMC Neurology, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Neurology
BMC Neurology
We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies in which individuals with migraine were randomized to oral lasmiditan 50 mg (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c39056830d16a6eba08b2dc2458b356
http://link.springer.com/article/10.1186/s12883-019-1420-5
http://link.springer.com/article/10.1186/s12883-019-1420-5
Publikováno v:
Cephalalgia
Background Sustained pain freedom is an important attribute of acute migraine therapies for patients and physicians. Here we report efficacy of the centrally penetrant, highly selective, 5-HT1F agonist lasmiditan on sustained pain freedom and other o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b3841f9559cd6a8d56183722d1ec3bd
https://doi.org/10.1177/0333102419859313
https://doi.org/10.1177/0333102419859313
Autor:
Joel Raskin, Deborah I. Friedman, John H. Krege, Andrew S. Buchanan, Louise Lombard, Sherie A. Dowsett, Stewart J. Tepper, Josephine K. Asafu-Adjei
Publikováno v:
Headache: The Journal of Head and Face Pain. 59:1052-1062
Trial design SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies conducted in the United States, as well as the United Kingdom and Germany (SPARTAN only). Individuals with migraine were randomized to receive oral lasmiditan 50 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d12a94e70847e52658f255496379d8a
https://doi.org/10.1111/head.13544
https://doi.org/10.1111/head.13544
Autor:
Ann Marie Hake, Joel Raskin, Grazia Dell'Agnello, Mark Belger, Kristin Kahle-Wrobleski, Gopalan Sethuraman, Catherine Reed, David Henley
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-11 (2018)
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy
Comparison of disease progression between placebo-group patients from randomised controlled trials (RCTs) and real-world patients can aid in assessing the generalisability of RCT outcomes. This analysis compared outcomes between community-dwelling pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29161dbe063ddbcf831be23898cf155a
http://link.springer.com/article/10.1186/s13195-018-0360-4
http://link.springer.com/article/10.1186/s13195-018-0360-4
Publikováno v:
The journal of prevention of Alzheimer's disease. 6(2)
Background: Randomized placebo-controlled trials in the development of disease-modifying treatments for Alzheimer’s disease are typically of short duration (12–18 months), and health economic modeling requires extrapolation of treatment effects b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d764d6793e9cf523817c6f6be0d7ff29
https://pubmed.ncbi.nlm.nih.gov/30756115
https://pubmed.ncbi.nlm.nih.gov/30756115